Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7514-7522

  Kánai, Károly ^a   Arányi, Péter ^a   Böcskei, Zsolt ^a   Ferenczy, György ^a   Harmat, Veronika ^b   Simon, Kálmán ^a   Bátori, Sándor ^a   Náray Szabó, Gábor ^b,c   Hermecz, István ^a  

^a Chinoin Pharmaceutical and Chemical Works Ltd   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

N ACYL PROLYLPYRROLIDINE; PROLYL ENDOPEPTIDASE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME INHIBITION; HYDROGEN BOND; MOLECULAR DYNAMICS; MOLECULAR MODEL; X RAY DIFFRACTION;

BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HYDROGEN BONDING; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRROLIDINES; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57349144413     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800944x     Document Type: Article

References (91)

1. Yoshimoto, T.; Orlowski, R. C.; Walter, R. Postproline cleaving enzyme: identification as serine protease using active site specific inhibitors. Biochemistry 1977, 16, 2942-2948.
2. Moriyama, A.; Nakanishi, M.; Sasaki, M. Porcine muscle prolyl endopeptidase and its endogenous substrates. J. Biochem. (Tokyo) 1988, 104, 112-117.
3. Walter, R.; Shlank, H.; Glass, J. D.; Schwartz, I. L.; Kerenyi, T. D. Leucylglycinamide released from oxytocin by human uterine enzyme. Science 1971, 173, 827-829.
4. Koida, M.; Walter, R. Post-proline cleaving enzyme. Purification of this endopeotidase by affinity chromatography. J. Biol. Chem. 1976, 251, 7593-7599.
5. Yoshimoto, T.; Ogita, K.; Walter, R.; Koida, M.; Tsuru, D. Postproline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochem. Biophys. Acta 1979, 569, 184-192.
6. Orlowski, M.; Wilk, E.; Pearce, S.; Wilk, S. Purification and properties of prolyl endopeptidase from rabbit brain. J. Neurochem. 1979, 33, 461-469.
7. Knisatschek, H.; Bauer, K. Characterization of 'thyroliberin-deamidating enzyme' as a post-proline-cleaving enzyme. Partial purification and enzyme-chemical analysis of the enzyme from anterior pituitary tissue. J. Biol. Chem. 1979, 254, 10936-10943.
8. Kato, T.; Okada, M.; Nagatsu, T. Distribution of postproline cleaving enzyme in human brain and peripheral tissues. Mol Cell. Biochem. 1980, 32, 117-121.
9. Kalwant, S.; Porter, A. G. Purification and characterization of human brain prolyl endopeptidase. Biochem. J. 1991, 276, 237-244.
10. Goossens, F.; De Meester, I.; Vanhoof, G.; Scharpé, S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluid. Eur. J. Clin. Chem. Clin. Biochem. 1996, 34, 17-22.
11. Kovacs, G. L.; Bohus, B.; Versteeg, D. H. G.; De Kloet, E. R.; De Wied, D. Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjections into limbic-midbrain structures. Brain Res. 1979, 175, 303-314.
12. Maes, M.; Goossens, F.; Scharpé, S.; Meltzer, H. Y.; D'Hondt, P.; Cosyns, P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol. Psychiatry 1994, 35, 545-552.
13. Welches, W. R.; Brosnihan, K. B.; Ferrario, C. M. A comparison of properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life. Sci. 1993, 52, 1461-1480.
14. (a) Brandt, I.; Schärpe, S.; Lambeir, A. M. Suggested function for prolyl oligopeptidase: A puzzling paradox. Clin. Chim. Acta 2007, 377, 50-61.
15. (b) Williams, R. S. B. Pharmacogenetics in model systems: Defining a common mechanism of action for mood stabilizers. Prog. Neuropsychopharmacol Biol. Psychiatry 2005, 29, 1029-1037.
16. (c) Williams, R. S. B.; Cheng, L.; Mudge, A. W.; Harwood, A. J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002, 417, 292-295.
17. (d) Schulz, I.; Gerhartz, B.; Neubauer, A.; Holloschi, A.; Heiser, U.; Hafner, M.; Demuth, H.-U. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur. J. Biochem. 2002, 269, 5813-5820.
18. (a) García-Horsman, J. A.; Männistö, P. T.; Venäläinen, J. I. On the role of prolyl oligopeptidase in health and disease. Neuropeptidase 2007, 41, 1-24.
19. (b) Gass, J.; Khosla, C. Prolyl endopeptidase. Cell. Mol. Life Res. 2007, 64, 345-355.
20. (c) Williams, R. S. B. Prolyl oligopeptidase and bipolar disorder. Clin. Neurosci. Res. 2004, 4, 233-242.
21. Cacabelos, R.; Alvarez, A.; Lombardi, V.; Fernández-Novoa, L.; Corzo, L.; Pérez, P.; Laredo, M.; Pichel, V.; Hernández, A.; Varela, M.; Figuero, J., Jr.; Windisch, M.; Vigo, C. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000, 36, 415-499.
22. De Nanteuil, G.; Portevin, B.; Lepagnol, J. Prolyl endopeptidase inhibitors: a new class of memory enhancing drugs. Drugs Future 1998, 23, 167-179.
23. Vanhoof, G.; Goossens, F.; Hendriks, L.; De Meester, I.; Hendriks, D.; Vriend, G.; Van Broeckhoven, C.; Scharpé, S. Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene 1994, 149, 363-366.
24. Goossens, F.; De Meester, I.; Vanhoof, G.; Hendriks, D.; Vriend, G.; Scharpé, S. The purification, characterization and analysis of primary and secondary structure of prolyl endopeptidase from human lymphocytes. Evidence that the enzyme belongs to the α;/β hydrolase fold family. Eur. J. Biochem. 1995, 233, 432-441.
25. Polgár, L. Structural relationship between lipases and peptidases of the prolyl oligopeptidase family. FEBS Lett. 1992, 311, 281-284.
26. Fülöp, V.; Böcskei, Zs.; Polgár, L. Prolyl oligopeptidase: an unusual β-propeller domain regulates proteolysis. Cell 1998, 94, 161-170.
27. Böcskei, Zs.; Fuxreiter, M.; Náray-Szabó, G.; Szabó, E.; Polgár, L. Crystallization and preliminary X-ray analysis of porcine muscle prolyl oligopeptidase. Acta Crystallogr. 1998, D54, 1414-1415.
28. (a) Szeltner, Z.; Polgár, L. Structure, function and biological relevance of prolyl oligopeptidase. Curr. Protein Pept. Sci. 2008, 9, 96-107.
29. (b) Shan, L.; Mathews, I. I.; Khosla, C. Structural and mechanistic analysis of two prolyl endopeptidases: Role of interdomain dynamics in catalysis and specificity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3599-3604.
30. (c) Fuxreiter, M.; Magyar, Cs.; Juhász, T.; Szeltner, Z.; Polgár, L.; Simon, I. Flexibility of prolyl oligopeptidase: Molecular Dynamics and molecular framework analysis of the potential substrate pathways. Proteins 2005, 60, 504-512.
31. Yoshimoto, T.; Kawahara, K.; Matsubara, F.; Kado, K.; Tsuru, D. Comparison of inhibitory effects of prolinal-containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium. J. Biochem. 1985, 98, 975-979.
32. Fülöp, V.; Szeltner, Z.; Polgár, L. Catalysis of serine oligopeptidases is controlled by a gating filter mechanism. EMBO Rep. 2000, 1, 277-281.
33. Fülöp, V.; Szeltner, Z.; Renner, V.; Polgár, L. Structures of prolyl oligopeptidase substrate/inhibitor complexes. Use of inhibitor binding for titration of the catalytic histidine residue. J. Biol. Chem. 2001, 276, 1262-1266.
34. Szeltner, Z.; Rea, D.; Juhász, T.; Renner, V.; Mucsi, Z.; Orosz, G.; Fülöp, V.; Polgár, L. Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase. J. Biol. Chem. 2002, 277, 44597-44605.
35. Szeltner, Z.; Rea, D.; Renner, V.; Fülöp, V.; Polgár, L. Electrostatic effects and binding determinants in the catalysis of prolyl oligopeptidase. Site-specific mutagenesis at the oxyanion binding site. J. Biol. Chem. 2002, 277, 42613-42622.
36. (a) Haffner, C. D.; Diaz, C. J.; Miller, A. B.; Reid, R. A.; Madauss, K. P.; Hassel, A.; Hanlon, M. H.; Porter, D. J. T.; Becherer, J. D.; Carter, L. H. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP). Bioorg. Med. Chem. Lett. 2008, 18, 4360-4363.
37. (b) Jarho, E. M.; Venäläinen, J. I.; Poutiainen, S.; Leskinen, H.; Vepsnäläinen, J.; Christiaans, J. A. M.; Forsberg, M. M.; Männistö, P. T.; Wallén, E. A. A. 2(S)-(Cycloalk-1- enecarbonyl)-1-(4-phenylbutanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4- phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors. Bioorg. Med. Chem. 2007, 15, 2024-2031.
38. (c) Jarho, E. M.; Venäläinen, J. I.; Juntunen, J.; Yli-Kokko, A. L.; Vepsnäläinen, J.; Christiaans, J. A. M.; Forsberg, M. M.; Järvinen, T.; Männistö, P. T.; Wallén, E. A. A. An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5590-5593.
39. (d) Venäläinen, J. I.; Wallén, E. A.; A.; Poso, A.; García-Horsman, J. A.; Männistö, P. T. Synthesis and characterization of the novel fluorescent prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbonyl-6-aminocaproyl-L-prolyl-2(S)-hydroxyacetyl) pyrrolidine. J. Med. Chem. 2005, 48, 7093-7095.
40. (e) Jarho, E. M.; Wallén, E. A. A.; Christiaans, J. A. M.; Forsberg, M. M.; Venäläinen, J. I.; Männistö, P. T.; Gynther, J.; Poso, A. Dicarboxylic acid azacycle L-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme - inhibitor interactions. J. Med. Chem. 2005, 48, 4772-4782.
41. (f) Jarho, E. M.; Venäläinen, J. I.; Huuskonen, J.; Christiaans, J. A. M.; García-Horsman, J. A.; Forsberg, M. M.; Järvinen, T.; Gynther, J.; Männistö, P. T.; Wallén, E. A. A. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J. Med. Chem. 2004, 47, 5605-5607.
42. (g) Wallén, E. A. A.; Christiaans, J. A. M.; Jarho, E. M.; Forsberg, M. M.; Venäläinen, J. I.; Männistö, P. T.; Gynther, J. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(L-prolyl-pyrrolidine) amides. J. Med. Chem. 2003, 46, 4543-4551.
43. (h) Wallén, E. A. A.; Christiaans, J. A. M.; Saarinen, T. J.; Jarho, E. M.; Forsberg, M. M.; Venäläinen, J. I.; Männistö, P. T.; Gynther, J. Conformationally rigid N-acyl-5-alkyl-L- prolyl-pyrrolidines as prolyl oligopeptidase inhibitors. Bioorg. Med. Chem. 2003, 11, 3611-3619.
44. (i) Wallén, E. A. A.; Christiaans, J. A. M.; Forsberg, M. M.; Venäläinen, J. I.; Männistö, P. T.; Gynther, J. Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors. J. Med. Chem. 2002, 45, 4581-4584.
45. (j) Wallén, E. A. A.; Christiaans, J. A. M.; Saario, S. M.; Forsberg, M. M.; Venäläinen, J. I.; Paso, H. M.; Männistö, P. T.; Gynther, J. 4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorg. Med. Chem. 2002, 10, 2199-2206.
46. Kánai, K.; Erdõ, S.; Susán, E.; Fehér, M.; Sipos, J.; Podányi, B.; Szappanos, A.; Hermecz, I. Prolyl endopeptidase inhibitors: N-acyl derivatives of L-thioproline-pyrrolidine. Bioorg. Med. Chem. Lett. 1997, 7, 1701-1704.
47. Fehér, M.; Kánai, K.; Podányi, B.; Hermecz, I. Conformational analysis of two inhibitors of prolyl endopeptidase: comparison of 4-phenylbutyryl- and octanoyl-prolyl-pyrrolidine. Quant. Struct.-Act. Relat. 1997, 16, 136-141.
48. Kánai, K.; Feh́er, M.; Lopata, A.; Podányi, B.; Novák, I.; Susán, E.; Hermecz, I.; Arányi, P. Molecular modeling and CoMFA studies on prolyl endopeptidase inhibitors. Acta Pharm. Hung. 1999, 69, 240-246;
49. Chem. Abstr. 2000, 133, 86.
50. Hermecz, I.; Kánai, K. Prolyl endopeptidase inhibitors. Il Farmaco 2000, 55, 188-190.
51. Kánai, K.; Erdõ, S.; Szappanos, A.; Bence, J.; Hermecz, I.; Szvoboda, Gy.; Bátori, S.; Héja, G.; Balogh, M.; Horváth, Á.; Sípos, J.; Barta-Bodor, V.; Párkány, Zs.; Lakics, V.; Molár, P. Preparation of proline pyrrolidine amide derivatives as prolyl endopeptidase inhibitors. WO 97/07,116. Chem. Abstr. 1997, 126, 238661.
52. Fehér, M.; Kánai, K.; Hermecz, I.; Lopata, A.; Novák, I. A 3D-QSAR analysis of prolyl endopeptidase inhibitors. Quant. Struct. - Act. Relat. 1999, 18, 456-463.
53. Arai, H.; Nishioka, H.; Niwa, S.; Yamanaka, I.; Tanaka, Y.; Yoshinaga, K.; Kobayashi, N.; Miura, N.; Ikade, Y. Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships: in vitro inhibition of prolyl endopeptidase from canine brain. Chem. Pharm. Bull. 1993, 41, 1583-1588.
54. Chapman, J. M.; Cocolas, G. H.; Hall, I. H. Hypolipidemic activity of phthalimide derivatives. 1. N-substituted phthalimide derivatives. J. Med. Chem. 1979, 22, 1399-1402.
55. (a) Shaffer, J. W.; Steinberg, E.; Krimsley, V.; Winstead, M. B. Substitution in the hydantoin ring. VII. N-propionic acid and its ethyl ester and N-3-(2-cyanoethyl) derivatives. J. Med. Chem. 1968, 11, 462-466.
56. (b) Sayo, H.; Hosokawa, M. Result of spin immunoassay for simultaneous measurement of phenytoin and phenobarbital in serum compared with those of liquid chromatography. Chem. Pharm. Bull. 1998, 33, 2866-2870.
57. Nishio, T. (2 + 2) photocycloaddition of the carbon-nitrogen double bond of quinoxalin-2(1H)-ones to electron-deficient olefins. J. Org. Chem. 1984, 49, 827-832.
58. (a) Hagmann, W. K. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 2008, 51, 4359-4369.
59. (b) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008, 37, 320-330.
60. (c) Shah, P.; Westwell, A. D. The role of fluorine in medicinal chemistry. J. Enzyme Inhib. Med. Chem. 2007, 22, 527-540.
61. (d) Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: Looking beyond intuition. Science 2007, 317, 1881-1886.
62. (e) Yoder, N. C.; Kumar, K. Fluorinated amino acids in protein design and engineering. Chem. Soc. Rev. 2002, 31, 335-341.
63. (f) O'Hagan, D.; Rzepa, H. S. Some influences of fluorine in bioorganic chemistry. Chem. Commun. 1997, 645-652.
64. Posteis, H.-T.; König, W. A. What is the structure of peptide antibiotic Tü 1718 B? previously proposed structure disproved by synthesis. Liebigs Ann. Chem. 1992, 1281-1287.
65. (a) Demange, L.; Ménez, A. É.; Dugave, C. Practical synthesis of Boc and Fmoc protected 4-fluoro and 4-difluoroprolines from trans-4-hydroxyroproline. Tetrahedron Lett. 1998, 39, 1169-1172.
66. (b) Middleton, W. J. New fluorinating reagents. Dialkylaminosulfur fluorides. J. Org. Chem. 1975, 40, 574-578.
67. Podányi, B.; Bokotey, S.; Kánai, K.; Fehér, M.; Hermecz, I. Investigations on flexible prolyl-endopeptidase inhibitor in solution by NMR techniques. Magn. Reson. Chem. 1999, 37, 346-352.
68. Boström, J.; Norrby, P.-O.; Liljefors, T. Conformational energy penalties of protein-bound ligands. J. Comput. - Aided Mol. Des. 1998, 12, 383-396.
69. Polgár, L. pH-Dependent mechanism in the catalysis of prolyl oligopeptidase from pig muscle. Eur. J. Biochem. 1991, 197, 441-447.
70. Polgár, L. Prolyl oligopeptidases. Methods Enzymol. 1994, 244, 188-200.
71. Leslie, A. G. W. Molecular data processing. In Crystallographic Computing 5: From Chemistry to Biology, Moras, D., Podjarny, A., Thierry, J., Eds.; Oxford University Press: Oxford, 1991; chapter 4, pp 50-61.
72. BioteX, Version 1.0, Molecular Structure Corporation, The Woodlands, TX, 1995.
73. Evans, P. R. Proc. of CCP4 Study Weekend on Data Collection & Processing. Data Reduction 1993, 114-122.
74. French, S.; Wilson, K. On the treatment of negative intensity observations. Acta Crystallogr. 1978, A34, 517-525.
75. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. 1994, A50, 157-163.
76. Collaborative Computing Project 4 The CCP4 suite: programs for protein crystallography Acta Cryst. 1994, D50, 760-763.
77. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
78. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1994, A47, 110-119.
79. Brunger, A. T. XPLOR: A System for X-ray crystallography and NMR Version 3, Yale University, New Haven, CT, 1992.
80. Aqvist, J.; Medina, C.; Samuelsson, J.-E. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994, 7, 385-391.
81. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
82. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
83. Ferenczy, G. G. Charges derived from distributed multipole series. J. Comput. Chem. 1991, 12, 913-917.
84. Chipot, C.; Ángyán, J. G.; Ferenczy, G. G.; Scheraga, H. A. Transferable net atomic charges from a distributed multipole analysis for the description of electrostatic properties: a case study of saturated hydrocarbons. J. Phys. Chem. 1993, 97, 6628-6636.
85. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, Jr. J. A.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, Ö.; Tomas:, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komáromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.6; Gaussian, Inc.: Pittsburgh PA, 1998.
86. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327-341.
87. van Gunsteren, W. F.; Berendsen, H. J. C. Algorithms for macromolecular dynamics and constraint dynamics. Mol. Phys. 1977, 34, 1311-1327.
88. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNiola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684-3690.
89. SYBYL Version 6.7, Tripos. Inc., St. Louis, MO.
90. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
91. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 945-949.